Phase 4 N=4,019 Belimumab Assessment of Safety in SLE
Systemic Lupus Erythematosus
Primary: Number of Deaths - On Treatment Period (Week 52) — 8; 10 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=273 Oracea Soolantra Association in Participants With Severe Rosacea
Rosacea
Primary: Percent Change From Baseline in Inflammatory Lesion Count at Week 12 — -80.29; -73.56 percent change — p=0.032
Phase 4 N=63 An Efficacy Study of Canagliflozin or Sitagliptin to Determine Glucose Variability in Mexican Participants With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Glycemic Coefficient of Variation (CV) in Treatment Period 1 — -0.69; 0.24 Percentage of CV
Phase 4 N=20 Study Evaluating the Drug Interaction Potential of Luliconazole Cream 1% in Participants With Tinea Pedis and Tinea Cruris
Tinea Pedis · Tinea Cruris
Primary: Circulating Levels (Plasma Concentration) of Omeprazole Prior to Treatment With Luliconazole Cream 1% — 0; 0; 23.67; 196.30 ng/mL
Phase 4 N=75 Safety and Efficacy of Product 33525 (Luliconazole Cream 1%) in Pediatric Participants With Tinea Corporis
Tinea Corporis
Primary: Circulating Plasma Concentration of Luliconazole at Day 7 (Pre-Dose) — 4.63; NA nanograms/milliliter (ng/mL)
Phase 4 N=30 Maximal Use of Luliconazole Cream 1% in Pediatric Participants With Moderate to Severe Tinea Pedis or Tinea Cruris
Tinea Pedis · Tinea Cruris
Primary: Measurement of Circulating Plasma Levels of Luliconazole in Participants Who Had Tinea Pedis: Maximum Observed Plasma Concentration (Cmax) of Luliconazole — 3.27…
Phase 4 N=276 Efficacy & Safety of Nasal Influenza Immunisation in Children
Influenza Vaccines Efficacy and Safety
Primary: Vaccine Efficacy — 4; 2; 4; 0 Participants
Phase 4 N=330 Comparison Between Quadruple Regimens for Helicobacter Pylori Infection in Egypt
Helicobacter Pylori Infection
Primary: Percentage of Helicobacter Pylori Infection Cure — 102; 101; 91 Participants
Phase 4 N=154 Intravenous Lidocaine Randomized Comparative Effectiveness Trial
Abdominal Pain
Primary: Change in 0-10 Pain Scale Between Baseline and 90 Minutes — 5.0; 3.8 units on a scale
Phase 4 N=359 Clinical and Economic Implications of Genetic Testing for Warfarin Management
Blood Coagulation Disorders
Primary: Inpatient Length of Stay — 6.8; 7.2 days
Phase 4 N=240 Safety and Immunogenicity of Fluzone® Quadrivalent, Flublok® Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 2018-2019 Formulations
Influenza
Primary: Number of Participants (Group 1: Aged 6 to <36 Months) Reporting Solicited Injection Site Reactions and Systemic Reactions — 15; 3; 4; 2 Participants
Phase 4 N=36 ENLIGHTEN: Establishing Novel Antiretroviral (ARV) Imaging for Hair to Elucidate Non-Adherence
HIV/AIDS
Primary: Hair Antiretroviral Imaging — 156.4826656; 1092.130868; 0.501209; 3942.692396 Signal Abundance (au)
Phase 4 N=112 Conbercept Injection in Treatment of Severe Proliferative Diabetic Retinopathy
Proliferative Diabetic Retinopathy · Tractional Retinal Detachment
Primary: Best-corrected Visual Acuity — 1.25; 1.29; 1.16 LogMAR
Phase 4 N=24 Understanding Treatment Response With Naltrexone Among White Alcoholics
Alcoholism
Primary: Biphasic Alcohol Effects Scale:Total Mood — 6.94; 3.57; 6.50; 3.20 units on a scale
Phase 4 N=166 Efficacy and Safety of PRO-155 on Inflammation of the Conjunctival Surface in Subjects With Grade I-III Pterygium vs Placebo.
Pterygium · Ocular Pain · Ocular Inflammation
Primary: Conjunctival Hyperemia (CH) — 0; 0; 39; 29 eyes — p=0.133